Anti-Mullerian Hormone: Above and beyond Conventional Ovarian Reserve Markers

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Jamil, Zehra ^a   Fatima, Syeda Sadia ^a   Ahmed, Khalid ^a   Malik, Rabia ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; BIOLOGICAL MARKER;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; DISORDER OF SEX DEVELOPMENT; FEMALE; FEMALE INFERTILITY; GONAD DEVELOPMENT; HUMAN; MENSTRUAL CYCLE; OBESITY; OVARIAN RESERVE; OVARY CANCER; OVARY FOLLICLE; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; AGE; BLOOD; MALE; OVULATION INDUCTION; SECRETION (PROCESS); SEX DIFFERENCE;

AGE FACTORS; ANTI-MULLERIAN HORMONE; BIOMARKERS; FEMALE; HUMANS; MALE; OVARIAN FOLLICLE; OVARIAN RESERVE; OVULATION INDUCTION; SEX FACTORS;

EID: 84959198081     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/5246217     Document Type: Review

References (66)

1. M. Lindhardt Johansen, C. P. Hagen, T. H. Johannsen et al., "Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development," International Journal of Endocrinology, vol. 2013, Article ID 198698, 10 pages, 2013.
2. A. Karkanaki, C. Vosnakis, D. Panidis, "The clinical significance of anti-müllerian hormone evaluation in gynecological endocrinology," Hormones, vol. 10, no. 2, pp. 95-103, 2011.
3. D. Dewailly,C.Y.Andersen, A. Balenet al., "The physiology and clinical utility of anti-Müllerian hormone in women," Human Reproduction Update, vol. 20, no. 3, Article IDdmt062, pp. 370-385, 2014.
4. E. W. Freeman, M. D. Sammel,H. Lin, C. R. Gracia, "Antimullerian hormone as a predictor of time to menopause in late reproductive age women," The Journal of Clinical Endocrinology &Metabolism, vol. 97, no. 5, pp. 1673-1680, 2012.
5. T. W. Kelsey, P. Wright, S. M. Nelson, R. A. Anderson, W. H. B. Wallace, "A validated model of serum Anti-Müllerian hormone fromconception to menopause," PLoSONE, vol. 6, no. 7, Article ID e22024, 2011.
6. S. L. Broer, M. J. C. Eijkemans, G. J. Scheffer et al., "Anti-Müllerian hormone predicts menopause: a long-term followup study in normoovulatory women," The Journal of Clinical Endocrinology &Metabolism, vol. 96, no. 8, pp. 2532-2539, 2011.
7. S. Rice, K. Ojha, S. Whitehead, H. Mason, "Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: Relevance to polycystic ovaries," The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 3, pp. 1034-1040, 2007.
8. K. Watanabe, T. R. Clarke, A. H. Lane, X. Wang, P. K. Donahoe, "Endogenous expression of Mullerian inhibiting substance in early postnatal rat Sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 4, pp. 1624-1629, 2000.
9. I. Demeestere, F.Moffa, F. Peccatori, C. Poirot, E. Shalom-Paz, "Multiple approaches for individualized fertility protective therapy in cancer patients," Obstetrics and Gynecology International, vol. 2012,Article ID 961232, 12 pages, 2012.
10. P. Bhattacharya and A. F. Keating, "Ovarian metabolism of xenobiotics," Experimental Biology and Medicine, vol. 236, no. 7, pp. 765-771, 2011.
11. S. L. Broer, B. Mol, M. Dólleman, B. C. Fauser, F. J. M. Broekmans, "The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome," Current Opinion in Obstetrics and Gynecology, vol. 22, no. 3, pp. 193-201, 2010.
12. J. V. Jeppesen, R. A. Anderson, T. W. Kelsey et al., "Which follicles make the most anti-Müllerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection,"MolecularHuman Reproduction, vol. 19,no. 8, pp. 519-527, 2013.
13. I. B. Carlsson, J. E. Scott, J. A. Visser, O. Ritvos, A. P. N. Themmen, O. Hovatta, "Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro," Human Reproduction, vol. 21, no. 9, pp. 2223-2227, 2006.
14. A. L. L. Durlinger, M. J. G. Gruijters, P. Kramer et al., "Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary," Endocrinology, vol. 143, no. 3, pp. 1076-1084, 2002.
15. L. Kalich-Philosoph, H. Roness1, A. Carmely et al., "Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility," Science Translational Medicine, vol. 5, no. 185,Article ID 185ra62, 2013.
16. J. van Disseldorp, C. B. Lambalk, J. Kwee et al., "Comparison of inter-and intra-cycle variability of anti-Müllerian hormone and antral follicle counts," Human Reproduction, vol. 25, no. 1, pp. 221-227, 2010.
17. J. F. Randolph, S. D. Harlow, M. E. Helmuth, H. Zheng, D. S.McConnell, "Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle," Human Reproduction, vol. 29, no. 3, Article IDdet447, pp. 592-600, 2014.
18. R. Tal andD. B. Seifer, "Potentialmechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve," International Journal of Endocrinology, vol. 2013, Article ID 818912, 7 pages, 2013.
19. S. Lie Fong, J. A. Visser, C. K.Welt et al., "Serumanti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood,"TheJournal of Clinical Endocrinology and Metabolism, vol. 97, no. 12, pp. 4650-4655, 2012.
20. I.A. J. vanRooij, F. J.M. Broekmans, G. J. Scheffer et al., "Serum antimüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study," Fertility and Sterility, vol. 83, no. 4, pp. 979-987, 2005.
21. S. L. Broer, F. J. M. Broekmans, J. S. E. Laven, B. C. J. M. Fauser, "Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications," Human Reproduction Update, vol. 20, no. 5, pp. 688-701, 2014.
22. H. G. Burger, E. C. Dudley, D. M. Robertson, L. Dennerstein, "Hormonal changes in the menopause transition," Recent Progress in Hormone Research, vol. 57, pp. 257-275, 2002.
23. M. Perloe, D. P. Levy, E. S. Sills, "Strategies for ascertaining ovarian reserve among women suspected of subfertility," International Journal of Fertility and Women's Medicine, vol. 45, no. 3, pp. 215-224, 2000.
24. A. Bukman and M. J. Heineman, "Ovarian reserve testing and the use of prognostic models in patients with subfertility," Human Reproduction Update, vol. 7, no. 6, pp. 581-590, 2001.
25. S. A. Willis, T. J. Kuehl, A. M. Spiekerman, P. J. Sulak, "Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval," Contraception, vol. 74, no. 2, pp. 100-103, 2006.
26. C. H. Gravholt, "Clinical practice in Turner syndrome," Nature Reviews Endocrinology, vol. 1, no. 1, pp. 41-52, 2005.
27. S. Franks, H. Mason, D. Willis, "Follicular dynamics in the polycystic ovary syndrome," Molecular and Cellular Endocrinology, vol. 163, no. 1-2, pp. 49-52, 2000.
28. A. Colao, C. di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, "Medical therapy for clinically nonfunctioning pituitary adenomas," Endocrine-Related Cancer, vol. 15, no. 4, pp. 905-915, 2008.
29. S. M. Nelson, "Biomarkers of ovarian response: current and future applications," Fertility and Sterility, vol. 99,no. 4, pp. 963-969, 2013.
30. V. Smith, T. Osianlis, B. Vollenhoven, "A review of luteinizing hormone and its role in ovarian reserve testing," International Journal of Reproduction, Contraception, Obstetrics and Gynecology, vol. 3, no. 1, pp. 11-18, 2014.
31. A.Weghofer, S. Schnepf,D. Barad,N. Gleicher, "Theimpact of luteinizing hormone in assisted reproduction: a review," Current Opinion in Obstetrics and Gynecology, vol. 19, no. 3, pp. 253-257, 2007.
32. I. Noci, R. Biagiotti, M. Maggi, F. Ricci, A. Cinotti, G. Scarselli, "Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation," Human Reproduction, vol. 13, no. 3, pp. 531-534, 1998.
33. S. Chun, "Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome," Clinical and Experimental Reproductive Medicine, vol. 41, no. 2, pp. 86-91, 2014.
34. S. Iliodromiti, T. W. Kelsey, O. Wu, R. A. Anderson, S. M. Nelson, "The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature," Human Reproduction Update, vol. 20, no. 4, pp. 560-570, 2014.
35. C. K.Welt, "Regulation and function of inhibins in the normal menstrual cycle," Seminars in ReproductiveMedicine, vol. 22,no. 3, pp. 187-193, 2004.
36. S. Muttukrishna, H. Suharjono, H. McGarrigle, M. Sathanandan, "Inhibin B and anti-Mullerian hormone:markers of ovarian response in IVF/ICSI patients?" BJOG, vol. 111, no. 11, pp. 1248-1253, 2004.
37. M. R. Sowers, A. D. Eyvazzadeh, D. McConnell et al., "Antimullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition," Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 9, pp. 3478-3483, 2008.
38. Y. Makanji, J. Zhu, R. Mishra et al., "Inhibin at 90: from discovery to clinical application, a historical review," Endocrine Reviews, vol. 35, no. 5, pp. 747-794, 2014.
39. M. Krawczuk-Rybak, E. Leszczynska,M. Poznanska, B. Zelazowska-Rutkowska, J. Wysocka, "Anti-Müllerian hormone as a sensitive marker of ovarian function in young cancer survivors," International Journal of Endocrinology, vol. 2013, Article ID 125080, 6 pages, 2013.
40. K. J. Ryan, "Biochemistry of aromatase: significance to female reproductive physiology," Cancer Research, vol. 42, no. 8, supplement, pp. 3342s-3344s, 1982.
41. V.Mais, N. S. Cetel, K. N.Muse,M.E.Quigley,R.L.Reid, S. S. Yen, "Hormonal dynamics during luteal-follicular transition," The Journal of Clinical Endocrinology &Metabolism, vol. 64, no. 6, pp. 1109-1114, 1987.
42. J. L. Frattarelli,D. F. Lauria-Costab,B.T.Miller, P. A. Bergh, R. T. Scott Jr., "Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles," Fertility and Sterility, vol. 74, no. 3, pp. 512-517, 2000.
43. T.-H. Lee, C.-H. Liu, C.-C. Huang et al., "Serum anti-müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles," Human Reproduction, vol. 23, no. 1, pp. 160-167, 2008.
44. A. La Marca, G. Stabile, A. Carducci Artenisio, A. Volpe, "Serum anti-Mullerian hormone throughout the human menstrual cycle," Human Reproduction, vol. 21, no. 12, pp. 3103-3107, 2006.
45. S. M. Nelson, R. A. Anderson, F. J. Broekmans, N. Raine-Fenning, R. Fleming, A. La Marca, "Anti-Müllerian hormone: clairvoyance or crystal clear?" Human Reproduction, vol. 27, no. 3, pp. 631-636, 2012.
46. F. J. M. Broekmans, D. De Ziegler, C. M. Howles, A. Gougeon, G. Trew, F. Olivennes, "The antral follicle count: practical recommendations for better standardization," Fertility and Sterility, vol. 94, no. 3, pp. 1044-1051, 2010.
47. A. La Marca, S. Giulini, A. Tirelli et al., "Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology," Human Reproduction, vol. 22, no. 3, pp. 766-771, 2007.
48. S. M. Nelson, R. W. Yates, H. Lyall et al., "Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception," Human Reproduction, vol. 24, no. 4, pp. 867-875, 2009.
49. N. Josso, R. Rey, J.-Y. Picard, "Testicular anti-müllerian hormone: clinical applications in DSD," Seminars in Reproductive Medicine, vol. 30, no. 5, pp. 364-373, 2012.
50. L. Aksglaede, P. Christiansen, K. Sørensen et al., "Serum concentrations of Anti-Müllerian Hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism," Acta Paediatrica, International Journal of Paediatrics, vol. 100, no. 6, pp. 839-845, 2011.
51. M. M. Lee, M. Misra, P. K. Donahoe, D. T. MacLaughlin, "MIS/AMH in the assessment of cryptorchidism and intersex conditions," Molecular and Cellular Endocrinology, vol. 211, no. 1-2, pp. 91-98, 2003.
52. J. A. Visser, A. C. S. Hokken-Koelega, G. R. J. Zandwijken, A. Limacher, M. B. Ranke, C. E. Flück, "Anti-Müllerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment," Human Reproduction, vol. 28, no. 7, pp. 1899-1907, 2013.
53. S. Sahmay, T. Usta, C. T. Erel et al., "Is there any correlation between amh and obesity in premenopausal women?" Archives of Gynecology and Obstetrics, vol. 286, no. 3, pp. 661-665, 2012.
54. D. Rachón and H. Teede, "Ovarian function and obesity-interrelationship, impact on women's reproductive lifespan and treatment options," Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 172-179, 2010.
55. M. Metwally, W. L. Ledger, T. C. Li, "Reproductive endocrinology and clinical aspects of obesity inwomen," Annals of theNew York Academy of Sciences, vol. 1127,pp. 140-146, 2008.
56. K. P. Tremellen, M. Kolo,A.Gilmore,D.N. Lekamge, "Antim üllerian hormone as a marker of ovarian reserve," Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 45, no. 1, pp. 20-24, 2005.
57. A. P. Yates, O. Rustamov, S. A. Roberts et al., "Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF," Human Reproduction, vol. 26, no. 9, pp. 2353-2362, 2011.
58. Y. Tokura, O. Yoshino, S. Ogura-Nose et al., "The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment," Journal of Assisted Reproduction and Genetics, vol. 30, no. 6, pp. 821-825, 2013.
59. R. J. Norman, D. Dewailly, R. S. Legro, T. E. Hickey, "Polycystic ovary syndrome," The Lancet, vol. 370, no. 9588, pp. 685-697, 2007.
60. M. P. Lauritsen, J. G. Bentzen, A. Pinborg et al., "The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone," Human Reproduction, vol. 29, no. 4, pp. 791-801, 2014.
61. L. Bungum, F. Franssohn, M. Bungum, P. Humaidan, A. Giwercman, "The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women," PLoS ONE, vol. 8, no. 9, Article ID e68223, 2013.
62. T. B. Eilertsen, E. Vanky, S. M. Carlsen, "Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?" Human Reproduction, vol. 27, no. 8, pp. 2494-2502, 2012.
63. M. Rosendahl, C. Y. Andersen, N. la Cour Freiesleben, A. Juul, K. Løssl, A. N. Andersen, "Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age," Fertility and Sterility, vol. 94, no. 1, pp. 156-166, 2010.
64. R. A. Rey, C. Lhomme, I. Marcillac et al., "Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum -inhibin and estradiol," American Journal of Obstetrics & Gynecology, vol. 174, no. 3, pp. 958-965, 1996.
65. J. Teixeira, S. Maheswaran, P. K. Donahoe, "Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications," Endocrine Reviews, vol. 22, no. 5, pp. 657-674, 2001.
66. R. Fleming, F. Broekmans, C. Calhaz-Jorge et al., "Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation?" Reproductive BioMedicine Online, vol. 26, no. 5, pp. 431-439, 2013.